AI Insight
Patients with atrial fibrillation who require coronary interventions face competing clinical priorities that must be carefully balanced. These include stroke prevention through oral anticoagulation, prevention of cardiac ischemia and stent thrombosis through antiplatelet therapy, and minimization of bleeding risk that increases when anticoagulants are combined with one or two antiplatelet agents. The commentary addresses the challenge of determining optimal duration of combination antithrombotic therapy in this high-risk population.
Why it matters
This clinical dilemma affects a substantial patient population, as atrial fibrillation and coronary artery disease frequently coexist. Optimizing the duration and combination of antithrombotic therapy could reduce bleeding complications while maintaining protection against stroke and cardiac events, directly impacting patient safety and outcomes.
Understand the Science
Patients with atrial fibrillation are at high risk of stroke and bleeding, and as coronary artery disease commonly coexists, such patients can present with chronic coronary syndrome or acute coronary syndromes including unstable angina, often requiring percutaneous coronary intervention (PCI) with coronary stenting.1 In such patients with atrial fibrillation, there are four factors that have to be carefully balanced: stroke prevention with the use of oral anticoagulant (nowadays usually a direct oral anticoagulant [DOAC]), given the high thromboembolic risk; antiplatelets for reducing recurrent cardiac ischaemia, especially in association with unstable angina; antiplatelets to reduce stent thrombosis; and bleeding risks when oral anticoagulant is combined with one or more antiplatelets, with the risk increasing with one and even greater with two antiplatelets.